The US Food and Drug Administration (FDA) has recently approved the world's first automated insulin-delivery system. Medtronic's MiniMed 670G is specifically for patients with type 1 diabetes.
Medtronic's Automated Device
The system features Medtronic's most advanced algorithm called SmartGuard HCL. According to the diabetes magazine A Sweet Life, it's the latest innovation for the company. They were able to develop a fully automated closed loop system.
It's part of Medtronic's commitment of simplified and improved diabetes management. The said algorithm offers minimal input from the patient. At the same time, a greater glucose control is achieved.
It also allows therapy customization. Patients and providers will be able to choose from increasing levels of automation. This depends on what fits best with their diabetes management needs.
According to Engadget, MiniMed 670G uses the Guardian Sensor. It will detect glucose levels under the skin every five minutes. The automated device supplies enough insulin to keep the patient's blood sugar stable.
Though a manual insulin dose still has to be triggered after meals. The patients still have to enter mealtime carbohydrates. They should accept correction recommendations. The sensor should also be calibrated periodically.
The Treatment's Flaw
The treatment is only available for people who are fourteen years of age and older. However, there is a possibility of adding the patient populations. Apparently, studies about the expansion are still ongoing.
The Automated System's Commercial Release
Medtronic is set to release the MiniMed 670G in 2017. Employees, clinicians, educators and patients will be trained about the system. The said date will also ensure that payer coverage, market and manufacturing are well prepared. It was also revealed that users will be eligible for a Priority Access Program.
The report states that the regulatory approval of the MiniMed 670G will be in the summer of 2017. This is for those outside the US.
